Biotech · Private company · Coral Gables, FL, US
Catalyst Pharmaceuticals, Inc.
SEC CIK 0001369568
Track this companyFree. Adds Catalyst Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- amifampridine phosphatePhase 3 · Myasthenic Syndromes, CongenitalClinicalTrials.gov · fetched Nov 12, 2026
- Amifampridine PhosphatePhase 3 · Myasthenia Gravis, GeneralizedClinicalTrials.gov · fetched Nov 12, 2026
- Amifampridine PhosphatePhase 3 · Myasthenia Gravis, MuSKClinicalTrials.gov · fetched Nov 12, 2026
- CPP-109 vigabatrinPhase 2 · Methamphetamine DependenceClinicalTrials.gov · fetched Nov 12, 2026
- CPP-115Phase 1 · Cocaine DependencyClinicalTrials.gov · fetched Nov 12, 2026
- Amifampridine PhosphateCongenital Myasthenic SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- VamoroloneDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMITRECRUITING · started Sep 25, 2024ClinicalTrials.gov NCT06564974 · fetched Nov 12, 2026
- Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)PHASE3 · TERMINATED · started Jun 11, 2018ClinicalTrials.gov NCT03579966 · fetched Nov 12, 2026
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGPHASE3 · COMPLETED · started Apr 18, 2018ClinicalTrials.gov NCT03304054 · fetched Nov 12, 2026
- Amifampridine Phosphate for the Treatment of Congenital Myasthenic SyndromesPHASE3 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02562066 · fetched Nov 12, 2026
- A Safety, Tolerability and Pharmacokinetic Study of CPP-115PHASE1 · COMPLETED · started Dec 1, 2011ClinicalTrials.gov NCT01493596 · fetched Nov 12, 2026
- Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine DependencePHASE2 · TERMINATED · started Jul 1, 2008ClinicalTrials.gov NCT00730522 · fetched Nov 12, 2026
- Treatment Use of 3,4 Diaminopyridine in Congenital MyastheniaNO_LONGER_AVAILABLEClinicalTrials.gov NCT03062631 · fetched Nov 12, 2026
- Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic SyndromeAPPROVED_FOR_MARKETINGClinicalTrials.gov NCT02189720 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Jul 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026